Current trends in the treatment of pneumonia due to multidrug-resistant Gram-negative bacteria.

Current trends in the treatment of pneumonia due to multidrug-resistant Gram-negative bacteria.

Watkins Richard R; van Duin David

F1000Research

2019

1905-07

Pneumonia is one of the most common infections worldwide. Morbidity, mortality, and healthcare costs increase substantially when pneumonia is caused by multidrug-resistant Gram-negative bacteria (MDR-GNB). The ongoing spread of antimicrobial resistance has made treating MDR-GNB pneumonia increasingly difficult. Fortunately, there have been some recent additions to our antibiotic armamentarium in the US and Europe for MDR-GNB, along with several agents that are in advanced stages of development. In this article, we review the risk factors for and current management of MDR-GNB pneumonia as well as novel agents with activity against these important and challenging pathogens.

Acinetobacter baumannii; antibiotics; Enterobacteriaceae; Pseudomonas aeruginosa

Article information provided for research and reference use only. All rights are retained by the journal listed under publisher and/or the creator(s).

8